SCHEMBL12464291

SCHEMBL12464291

CCN1CCC(N2CCCC2)C1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
SIGMAR1 Q99720 3/20 0.38
HRH3 Q9Y5N1 1/20 0.37
L3MBTL1 Q9Y468 4/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
L3MBTL3 Q96JM7 4/20 0.36
MBTD1 Q05BQ5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17946881 1.00 KMT2A (0.40) KMT2ASMN1; SMN2SIGMAR1HRH3L3MBTL1
SCHEMBL11919351 0.98 SIGMAR1 (0.41) KMT2ASMN1; SMN2SIGMAR1HRH3L3MBTL1
SCHEMBL4402941 0.88 SIGMAR1 (0.50) SIGMAR1
SCHEMBL26282856 0.87 KMT2A (0.47) KMT2ASMN1; SMN2SIGMAR1
SCHEMBL26280673 0.87 KMT2A (0.47) KMT2ASMN1; SMN2SIGMAR1
SCHEMBL26280669 0.87 KMT2A (0.47) KMT2ASMN1; SMN2SIGMAR1
SCHEMBL3439943 0.86 KMT2A (0.50) KMT2ASMN1; SMN2HRH3L3MBTL1ALDH1A1
SCHEMBL17722606 0.86 SIGMAR1 (0.53) SIGMAR1
SCHEMBL17722612 0.86 SIGMAR1 (0.53) SIGMAR1
SCHEMBL17722640 0.86 SIGMAR1 (0.53) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. 2023-05-11 US disclosed
US-20210087190-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-25 US disclosed
US-20190152969-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF INVENTISBIO SHANGHAI LTD. (CN) 2019-05-23 US disclosed
US-9745321-B2 Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2017-08-29 US disclosed
US-20160214994-A1 FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2016-07-28 US disclosed
US-20140171407-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2014-06-19 US disclosed
US-20110183938-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2011-07-28 US disclosed
US-20100324009-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-23 US disclosed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214994-A1 FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF PIK3CA, WEE1, TKFC KMT2A 3684/4885SMN1; SMN2 4341/4885SIGMAR1 3023/4885
US-20190152969-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF EGFR, WEE1, DPYD KMT2A 4145/4885SMN1; SMN2 4575/4885SIGMAR1 3266/4885
US-20100324009-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 KMT2A 1686/4885SMN1; SMN2 45/4885SIGMAR1 143/4885
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS SULT2A1, STS, SULT1A1 KMT2A 1686/4885SMN1; SMN2 45/4885SIGMAR1 143/4885
US-20110183938-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B KMT2A 2280/4885SMN1; SMN2 2262/4885SIGMAR1 4816/4885
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN3, NSUN2 KMT2A 2797/4885SMN1; SMN2 551/4885SIGMAR1 2067/4885
US-20140171407-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B KMT2A 2280/4885SMN1; SMN2 2262/4885SIGMAR1 4816/4885
US-20210087190-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 KMT2A 3229/4885SMN1; SMN2 2980/4885SIGMAR1 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.